Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arbutus Biopharma Q4 EPS $(0.12), Inline, Sales $2.15M Miss $4.79M Estimate

Author: Benzinga Newsdesk | February 29, 2024 08:36am
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $2.15 million which missed the analyst consensus estimate of $4.79 million by 55.22 percent. This is a 65.65 percent decrease over sales of $6.25 million the same period last year.

Posted In: ABUS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist